Informació de contacte
Departament de Farmacologia, Toxicologia i Química Terapèutica
Departament de Farmacologia, Toxicologia i Química Terapèutica Unitat de Toxicologia. Facultat de Farmàcia. Universitat de Barcelona. Av. Joan XXIII 27-31 +34 606587010 vruizdeporras(a)ub.edu
Formació acadèmica
Llicenciatura en Biologia (UB)
Doctorat en Biomedicina (UAB)
Màster en Investigació Clínica Aplicada en Ciències de la Salud (UAB)
Publicacions rellevants
Ruiz de Porras V; Bystrup S; Martínez-Cardús A; Pluvinet R; Sumoy L; Howells L; James MI; Iwuji C; Manzano JL; Layos L; Bugés C; Abad A; Martínez-Balibrea E. Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway.
En
Scientific Reports.
2016
. https://doi.org/10.1038/srep24675Ruiz de Porras, V; Bystrup, S; Cabrero-de Las Heras, S; Musulén, E; Palomero, L; Alonso, MH; Nieto, R; Arango, D; Moreno, V; Queralt, C; Manzano, JL; Layos, L; Bugés, C; Martinez-Balibrea, E. Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients.
En
Cancers.
Volum 11.
Número 10.
2019
. Repositori InstitucionalRuiz de Porras V; Wang XC; Palomero L; Marin-Aguilera M; Solé-Blanch C; Indacochea A; Jimenez N; Bystrup S; Bakht M; Conteduca V; Piulats JM; Buisan O; Suarez JF; Pardo JC; Castro E; Olmos D; Beltran H; Mellado B; Martinez-Balibrea E; Font A; Aytes A. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
En
European Urology.
2020
. https://doi.org/10.1016/j.eururo.2020.10.001Font A; Ruiz de Porras V; Valderrama BP; Ramirez JL; Nonell L; Virizuela JA; Anido U; González-Del-Alba A; Lainez N; Llorente MDM; Jiménez N; Mellado B; García-Donas J; Bellmunt J. Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma.
En
Cancers.
2021
. https://doi.org/10.3390/cancers13246235Ruiz de Porras V; Font A; Aytes A. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
En
Cancer Letters.
2021
. https://doi.org/10.1016/j.canlet.2021.08.033Ruiz de Porras V; Figols M; Font A; Pardina E. Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury.
En
Life Sciences.
2023
. Repositori InstitucionalRuiz de Porras V; Layos L; Martínez-Balibrea E. Curcumin: A therapeutic strategy for colorectal cancer?.
En
Seminars in Cancer Biology.
2020
. https://doi.org/10.1016/j.semcancer.2020.09.004Ruiz de Porras V; Bernat-Peguera A; Alcon C; Laguia F; Fernández-Saorin M; Jiménez N; Senan-Salinas A; Solé-Blanch C; Feu A; Marín-Aguilera M; Pardo JC; Ochoa-de-Olza M; Montero J; Mellado B; Font A. Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.
En
Frontiers in Pharmacology.
Volum 15.
2024
. Repositori InstitucionalAranka Brockmueller, Vicenç Ruiz de Porras , Mehdi Shakibaei. Curcumin and its anti-colorectal cancer potential: From mechanisms of action to autophagy.
En
Phytotherapy Research.
Volum 38.
Número 7.
2024
. https://doi.org/10.1002/ptr.8220Meyer C, Brockmueller A, Ruiz de Porras V, Shakibaei M. Microbiota and Resveratrol: How Are They Linked to Osteoporosis?.
En
Cells.
Volum 13.
Número 13.
2024
. https://doi.org/10.3390/cells13131145